Epub: Moberly JB et al. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients. J Neuroimmunol 2012 Mar.
CS-0777 is a selective sphingosine 1-phosphate receptor-1 modulator under investigation for treatment of MS. The investigators conducted an open-label, pilot study in 25 MSers to assess the safety, pharmacokinetics, pharmacodynamics and exploratory efficacy of oral CS-0777 (0.1, 0.3 and 0.6mg), administered once weekly or every other week for 12weeks. CS-0777 resulted in a pronounced, dose-dependent decrease in lymphocytes and CD4 T cell subsets, which returned to baseline within 4 weeks after the last dose. Overall, CS-0777 was safe and well-tolerated. These results require confirmation in a double-blind, placebo-controlled and adequately powered phase 2 study in MS.
The S1P1 receptor
Pharmaceutical companies are like lemmings or should I say sharks, so once one gets a smell of blood or in this case money they all follow in the path of those that go before them. Maybe they can form a cartel to fix price as there seldom seems to be a price war. CS-0777 is another version of Fingolimod (Gilenya). There are a number of others. Will this have the same side-effect profile as Fingolimod (Gilenya)? Yes, if the mechanism of action and the side effects are mediated via the sphingosine 1-phosphate receptor-1.